Immune disease medicament comprising a modulator of the binding between a heparin binding domain of thrombospondin-1 and a beta1 integrin
AssigneesHadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
InventorsDror Mevorach, Alon Krispin, Yaniv Bledi, Michal Linial
Life of this patent
Estimating the term…
Abstract
An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.
Claims4
A method of treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a substantially isolated heparin-binding domain (HBD) of thrombospondin 1, wherein said HBD of thrombospondin-1 inhibits differentiation of immunostimulatory/mature antigen-presenting cells, thereby treating the inflammatory bowel disease.
Dependencies are inferred from the claim text.